Here’s their press release
NettaLife claims it has gained the first approval for a cannabidiol (CBD) veterinary medicine as a pharmaceutical product.
The company has secured authorization for its NettaVet 10% CBD formulation for pets in Uruguay. The product’s specific indications have not been disclosed.
NettaLife is a pet health and nutrition subsidiary of RAMM Pharma—a Canadian specialist in plant-derived cannabinoid pharmaceutical products. NettaLife obtained a license for NettaVet 10% from the Uruguayan Ministry of Agriculture, Livestock and Fisheries (MGAP).
RAMM explained NettaVet 10% is “distinctly different from other products sold commercially,” as the latter are typically food supplements or nutraceutical products that have not undergone stability, efficacy or other testing by a health agency.
Production and commercial sales of NettaVet 10% are expected to “commence immediately.” NettaLife is in the process of obtaining approval and registration for additional formulations of the product. It has also initiated clinical trials to study the efficacy of its NettaVet pet cannabinoid formulations for the “treatment of various pathologies in animals.” NettaLife has been developing NettaVet CBD veterinary products since 2018.
The company believes NettaVet products will offer a “natural, holistic medical alternative for animal care” and that “may produce therapeutic results for diagnosed conditions such as idiopathic epilepsy, canine lymphoma and anxiety, without the negative side effects of traditional veterinary medications.”
NettaLife said: “CBD is renowned as a very well-tolerated medication and nutraceutical that doesn’t produce harmful side effects. In addition, CBD-based products are believed not to damage the kidneys, liver, or gastrointestinal system. This business line will synergistically leverage RAMM’s pharmaceutical expertise to continue to further the development of its products which will begin being rolled out in 2021.”
Elsewhere in the CBD pet health space, Australian firm CannPal Therapeutics is expecting to commercialize its DermaCann nutraceutical for improved skin and health function in dogs this year. The company is also developing CPAT-01 to target pain and inflammation in companion animals, with a focus on dogs.
CannPal is to be acquired by compatriot business AusCann Group. The deal will see AusCann acquire 100% of CannPal’s shares for approximately A$17.5 million ($12.9 million). The transaction is expected to maximize R&D across both animal and human health development programs, giving CannPal access to resources to advance its pipeline and growth objectives.